Pharvaris (PHVS) Expected to Announce Quarterly Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Pharvaris to post earnings of ($0.80) per share for the quarter.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.06. On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $16.81 on Tuesday. The firm has a market cap of $878.99 million, a price-to-earnings ratio of -6.00 and a beta of -2.85. The firm has a fifty day moving average price of $15.31 and a 200 day moving average price of $17.80. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50.

Analyst Upgrades and Downgrades

Several analysts have commented on PHVS shares. JMP Securities boosted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st. Cantor Fitzgerald initiated coverage on Pharvaris in a report on Tuesday, April 29th. They issued an “overweight” rating and a $28.00 target price on the stock.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.